Peter Bias
Ulm, BW, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 22 publications
Efficacy and safety of lipegfilgrastim versus pegfilgrastim in elderly patients with aggressive B cell non-Hodgkin lymphoma (B-NHL): results of the randomized, open-label, non-inferiority AVOID neutropenia study.
Journal: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
Published: April 30, 2020
The Path Towards a Tailored Clinical Biosimilar Development.
Journal: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy
Published: April 09, 2020
A Phase 2, International, Multicenter, Open-label Clinical Trial of Subcutaneous Tbo-Filgrastim in Pediatric Patients With Solid Tumors Undergoing Myelosuppressive Chemotherapy.
Journal: Journal of pediatric hematology/oncology
Published: July 06, 2019
Comment on "Biosimilar FSH preparations- are they identical twins or just siblings?"
Journal: Reproductive biology and endocrinology : RB&E
Published: August 09, 2016
A pharmacokinetic study of lipegfilgrastim in children with Ewing family of tumors or rhabdomyosarcoma.
Journal: Cancer chemotherapy and pharmacology
Published: June 08, 2016
Safety and efficacy of Ovaleap® (recombinant human follicle-stimulating hormone) for up to 3 cycles in infertile women using assisted reproductive technology: a phase 3 open-label follow-up to Main Study.
Journal: Reproductive biology and endocrinology : RB&E
Published: March 14, 2016
Efficacy and safety of lipegfilgrastim compared with placebo in patients with non-small cell lung cancer receiving chemotherapy: post hoc analysis of elderly versus younger patients.
Journal: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
Published: December 11, 2015
Randomized, active-controlled, comparative phase 3 efficacy and safety equivalence trial of Ovaleap® (recombinant human follicle-stimulating hormone) in infertile women using assisted reproduction technology (ART).
Journal: Reproductive biology and endocrinology : RB&E
Published: October 14, 2015
Cardiovascular Morbidity and Pure Red Cell Aplasia Associated With Epoetin Theta Therapy in Patients With Chronic Kidney Disease: A Prospective, Noninterventional, Multicenter Cohort Study.
Journal: Clinical therapeutics
Published: August 11, 2015
Phase 1 safety, tolerability, and pharmacokinetic study of single ascending doses of XM17 (recombinant human follicle-stimulating hormone) in downregulated healthy women.
Journal: International journal of women's health
Published: July 28, 2015
Phase I, two-way, crossover study to demonstrate bioequivalence and to compare safety and tolerability of single-dose XM17 vs Gonal-f® in healthy women after follicle-stimulating hormone downregulation.
Journal: Reproductive biology and endocrinology : RB&E
Published: July 08, 2015
Clinical safety of tbo-filgrastim, a short-acting human granulocyte colony-stimulating factor.
Journal: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
Published: May 26, 2015
Last Updated: 09/26/2026